Why Hims & Hers (HIMS) rose 10.54%
Hims & Hers (HIMS) rose 10.54% on October 9, 2026 — Peptide demand tailwind lifts Hims despite Citi's downside.
What happened
Hims & Hers rose on a peptide demand tailwind, with the stock jumping about 7% on the news and closing up 10.5% on the day.
Why it moved
Peptide products are a new growth line, so rising demand lifts the forward revenue outlook and justifies a higher multiple. That re-rating is what drives the move, not a one-time earnings beat.
Why it matters
Hims sits in the Meme & Retail Squeezes theme, where retail-heavy names with strong narratives tend to trade on sentiment and momentum more than on hard numbers.
What would break the thesis
Citi's flagged 17% downside is the counterpoint: if peptide growth slows or guidance weakens, the multiple can compress fast.